A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT ID: NCT05347095

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

288 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-27

Study Completion Date

2027-03-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fistulizing Crohns Disease Perianal Crohns Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: Guselkumab

Participants will receive guselkumab Dose 1 intravenous (IV) infusion followed by Dose 2 subcutaneously (SC). Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) period and continue to receive guselkumab.

Group Type EXPERIMENTAL

Guselkumab

Intervention Type DRUG

Guselkumab will be administered subcutaneously/IV infusion.

Placebo

Intervention Type DRUG

Matching placebo will be administered subcutaneously/IV infusion.

Group 2: Guselkumab

Participants will receive guselkumab Dose 1 IV infusion followed by Dose 3 SC. Participants will receive matching placebo to maintain the blind. At Week 24, guselkumab Dose 3 SC non-responders will switch to receive guselkumab dose 2 SC. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.

Group Type EXPERIMENTAL

Guselkumab

Intervention Type DRUG

Guselkumab will be administered subcutaneously/IV infusion.

Placebo

Intervention Type DRUG

Matching placebo will be administered subcutaneously/IV infusion.

Group 3: Placebo

Participants will receive placebo IV infusion followed by placebo SC. At Week 24, placebo non-responders will continue to receive guselkumab Dose 4 followed by guselkumab Dose 2 SC. Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.

Group Type EXPERIMENTAL

Guselkumab

Intervention Type DRUG

Guselkumab will be administered subcutaneously/IV infusion.

Placebo

Intervention Type DRUG

Matching placebo will be administered subcutaneously/IV infusion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Guselkumab

Guselkumab will be administered subcutaneously/IV infusion.

Intervention Type DRUG

Placebo

Matching placebo will be administered subcutaneously/IV infusion.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CNTO1959

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have a diagnosis of Crohn's disease with a minimum duration of at least 3 months
* Has at least one active draining perianal fistula as a complication of Crohn's disease, confirmed by screening magnetic resonance imaging (MRI) results
* Has previously demonstrated lack of initial response (that is primary non-responders), responded initially but then lost response with continued therapy (that is secondary non-responders), or were intolerant to a maximum of 2 classes of advanced drug therapies at a dose approved for the treatment of Crohn's disease (that is infliximab, adalimumab, certolizumab pegol, vedolizumab, or approved biosimilars for these agents) or JAK inhibitors licensed for Crohn's disease treatment (that is, upadacitinib)

Exclusion Criteria

* Has a very severe luminal disease activity
* History of concurrent rectovaginal fistulas (other types of concurrent fistula should be confirmed with the sponsor), rectal and/or anal stenosis, stoma or functioning ostomy (include all current stoma types abscess or collections which are not properly drained) colonic mucosal dysplasia or pre-cancerous lesions that have not been removed, demyelinating disease, or systemic lupus erythematosus
* Has complications of CD, such as symptomatic strictures or stenoses, short gut syndrome, or any other manifestation that might be anticipated to require surgery or preclude fistula evaluation
* Any medical contraindications preventing study participation
* Has a history of ongoing, chronic or recurrent enteral or systemic infectious disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Janssen-Cilag Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janssen-Cilag Ltd. Clinical Trial

Role: STUDY_DIRECTOR

Janssen-Cilag Ltd.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Yale University

New Haven, Connecticut, United States

Site Status

University of Miami

Miami, Florida, United States

Site Status

Gastroenterology Group Of Naples

Naples, Florida, United States

Site Status

AdventHealth Medical Group Blood & Marrow Transplant at Orlando

Orlando, Florida, United States

Site Status

Kansas University Medical Center

Kansas City, Kansas, United States

Site Status

University of Kentucky Chandler Medical Center

Lexington, Kentucky, United States

Site Status

University of Louisville

Louisville, Kentucky, United States

Site Status

Washington University School Of Medicine

St Louis, Missouri, United States

Site Status

Mount Sinai School of Medicine

New York, New York, United States

Site Status

Digestive Disease Specialists Inc

Oklahoma City, Oklahoma, United States

Site Status

Gastro One

Germantown, Tennessee, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Tyler Research Institute, LLC

Tyler, Texas, United States

Site Status

Swedish Medical Center

Seattle, Washington, United States

Site Status

Flinders Medical Centre

Adelaide, , Australia

Site Status

St Vincent's Hospital - Melbourne

Fitzroy, , Australia

Site Status

Liverpool Hospital

Liverpool, , Australia

Site Status

Fiona Stanley Hospital

Murdoch, , Australia

Site Status

Royal Prince Alfred Hospital

Newtown, , Australia

Site Status

Royal Adelaide Hospital

North Terrace, , Australia

Site Status

Royal Melbourne Hospital

Parkville, , Australia

Site Status

Royal Perth Hospital

Perth, , Australia

Site Status

Mater Hospital

South Brisbane, , Australia

Site Status

Hopital Erasme

Brussels, , Belgium

Site Status

Ziekenhuis Oost-Limburg

Genk, , Belgium

Site Status

UZ Leuven

Leuven, , Belgium

Site Status

CHU Sart Tilman

Liège, , Belgium

Site Status

University of Alberta- Ziedler Ledcor Centre

Edmonton, Alberta, Canada

Site Status

Nova Scotia Health Authority

Halifax, Nova Scotia, Canada

Site Status

London Health Sciences Centre

London, Ontario, Canada

Site Status

Mount Sinai Hospital

Toronto, Ontario, Canada

Site Status

McGill University Health Centre

Montreal, Quebec, Canada

Site Status

Nemocnice Ceske Budejovice a s

České Budějovice, , Czechia

Site Status

ISCARE a.s.

Prague, , Czechia

Site Status

Alexandria University Hospital

Alexandria, , Egypt

Site Status

National Hepatology and Tropical Medicine Research Institute

Cairo, , Egypt

Site Status

Ain Shams University Hospital

Cairo, , Egypt

Site Status

Cairo university

Giza, , Egypt

Site Status

Clinique Ambroise Pare

Neuilly-sur-Seine, , France

Site Status

CHU de Nice Hopital de l Archet

Nice, , France

Site Status

Hopital Saint Joseph

Paris, , France

Site Status

Centre Hospitalier Lyon Sud

Pierre-Bénite, , France

Site Status

CHRU Hopital de Pontchaillou

Rennes, , France

Site Status

CHRU Nancy Brabois

Vandœuvre-lès-Nancy, , France

Site Status

Charite - Campus Mitte

Berlin, , Germany

Site Status

JWG-University Hospital

Frankfurt, , Germany

Site Status

Universitatsklinikum Schleswig Holstein Kiel

Kiel, , Germany

Site Status

Universitaetsklinikum Mannheim

Mannheim, , Germany

Site Status

Universitaetsklinikum Ulm

Ulm, , Germany

Site Status

Evangelismos General Hospital of Athens

Athens, , Greece

Site Status

Hippokration Hospital

Athens, , Greece

Site Status

Sotiria General State Hospital of Chest Diseases

Athens, , Greece

Site Status

Alexandra General Hospital of Athens

Athens Attica, , Greece

Site Status

University Hospital of Heraklion

Heraklion, , Greece

Site Status

University Hospital Of Larissa

Larissa, , Greece

Site Status

Patras University Hospital

Pátrai, , Greece

Site Status

Hippokration Hospital

Thessaloniki, , Greece

Site Status

Magyar Honvedseg Egeszsegugyi Kozpont

Budapest, , Hungary

Site Status

Semmelweis Egyetem

Budapest, , Hungary

Site Status

Semmelweis Egyetem

Budapest, , Hungary

Site Status

Semmelweis Egyetem

Budapest, , Hungary

Site Status

Pecsi Tudomanyegyetem Orvostudomanyi Es Egeszsegtudomanyi Centrum, I. Belgyogyaszati Klinika

Pécs, , Hungary

Site Status

Szegedi Tud Egyetem Szent Gyorgyi Albert Klin Kozp

Szeged, , Hungary

Site Status

Haemek Medical Center

Afula, , Israel

Site Status

Rambam Medical Center

Haifa, , Israel

Site Status

Shaare Zedek Medical Center

Jerusalem, , Israel

Site Status

Rabin Medical Center Beilinson Campus

Petah Tikva, , Israel

Site Status

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

Milan, , Italy

Site Status

Ospedale Classificato Equiparato Sacro Cuore Don Calabria di Negrar

Negrar ( Ve), , Italy

Site Status

Azienda Ospedaliera Universitaria Pisana

Pisa, , Italy

Site Status

Azienda Ospedaliera G.Salvini Ospedale di Rho

Rho, , Italy

Site Status

Policlinico Universitario Agostino Gemelli

Roma, , Italy

Site Status

Istituto Clinico Humanitas

Rozzano, , Italy

Site Status

Casa Sollievo della Sofferenza

San Giovanni Rotondo, , Italy

Site Status

KOKIKAI Tokatsu Tsujinaka Hospital

Abiko, , Japan

Site Status

Fukuoka University Chikushi Hospital

Chikushino-shi, , Japan

Site Status

Hospital of the University of Occupational and Enviromental Health

Fukuoka, , Japan

Site Status

Fukuoka University Hospital

Fukuoka, , Japan

Site Status

Kitakyushu Municipal Medical Center

Fukuoka-ken, , Japan

Site Status

Hiroshima University Hospital

Hiroshima, , Japan

Site Status

Sameshima Hospital

Kagoshima, , Japan

Site Status

Nara Medical University Hospital

Kashihara, , Japan

Site Status

Tsujinaka Hospital Kashiwanoha

Kashiwa, , Japan

Site Status

Nagasaki University Hospital

Nagasaki, , Japan

Site Status

Kojunkai Daido Clinic

Nagoya, , Japan

Site Status

Nagoya University Hospital

Nagoya, , Japan

Site Status

The Hospital of Hyogo College of Medicine

Nishinomiya, , Japan

Site Status

Okayama University Hospital

Okayama, , Japan

Site Status

Kinshukai Infusion Clinic

Osaka, , Japan

Site Status

JOHAS Osaka Rosai Hospital

Sakai, , Japan

Site Status

Sapporo Higashi Tokushukai Hospital

Sapporo, , Japan

Site Status

Tokyo Yamate Medical Center

Shinjuku-ku, , Japan

Site Status

Matsuda Hospital

Shizuoka, , Japan

Site Status

Osaka University Hospital

Suita, , Japan

Site Status

Kyorin University Hospital

Tokyo, , Japan

Site Status

Ieda Hospital

Toyota, , Japan

Site Status

Mie University Hospital

Tsu, , Japan

Site Status

Yokkaichi Hazu Medical Center

Yokkaichi, , Japan

Site Status

Yokohama Municipal Citizen's Hospital

Yokohama, , Japan

Site Status

The Speciality Hospital (TSH) / Advanced Clinical Center

Amman, , Jordan

Site Status

Jordan University Hospital

Amman, , Jordan

Site Status

Abdali Hospital

Amman, , Jordan

Site Status

Irbid Specialty Hospital

Irbid, , Jordan

Site Status

King Abdullah University Hospital

Irbid, , Jordan

Site Status

Academisch Medisch Centrum Universiteit van Amsterdam

Amsterdam, , Netherlands

Site Status

Radboudumc

Nijmegen, , Netherlands

Site Status

Erasmus MC

Rotterdam, , Netherlands

Site Status

UMC Utrecht

Utrecht, , Netherlands

Site Status

Gastromed Kralisz Romatowski Stachurska Sp. j.

Bialystok, , Poland

Site Status

Centrum Medyczne Promed

Krakow, , Poland

Site Status

Centrum Medyczne Med Gastr

Lodz, , Poland

Site Status

Centrum Medyczne Medyk

Rzeszów, , Poland

Site Status

Twoja Przychodnia - Szczecinskie Centrum Medyczne

Szczecin, , Poland

Site Status

GASTROMED Kopon Zmudzinski i wspolnicy SP j Specjalistyczne Centrum Gastrologii i Endoskopii

Torun, , Poland

Site Status

WIP Warsaw IBD Point Profesor Kierkus

Warsaw, , Poland

Site Status

Melita Medical Sp. z o.o.

Wroclaw, , Poland

Site Status

Centrum Medyczne Oporow

Wroclaw, , Poland

Site Status

Uls Braga - Hosp. Braga

Braga, , Portugal

Site Status

Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos

Lisbon, , Portugal

Site Status

H. Santo António - Centro Hospitalar do Porto

Porto, , Portugal

Site Status

King Fahad Specialist hospital

Dammam, , Saudi Arabia

Site Status

King Abdulaziz Medical City

Jeddah, , Saudi Arabia

Site Status

King Saud University Medical City

Riyadh, , Saudi Arabia

Site Status

King Faisal Specialist Hospital & Research Center

Riyadh, , Saudi Arabia

Site Status

Inje University Haeundae Paik Hospital

Busan, , South Korea

Site Status

Yeungnam University Hospital

Daegu, , South Korea

Site Status

Seoul National University Bundang Hospital

Gyeonggi-do, , South Korea

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Gangnam Severance Hospital, Yonsei University Health System

Seoul, , South Korea

Site Status

Hosp Clinic de Barcelona

Barcelona, , Spain

Site Status

Hosp. Arquitecto Marcide

Ferrol, , Spain

Site Status

Hosp. Univ. Dr. Josep Trueta

Girona, , Spain

Site Status

Hosp. Univ. de La Princesa

Madrid, , Spain

Site Status

Hosp. Univ. Pta. de Hierro Majadahonda

Majadahonda, , Spain

Site Status

Hosp. Virgen Macarena

Seville, , Spain

Site Status

Hosp. Alvaro Cunqueiro

Vigo, , Spain

Site Status

Hosp. Univ. Miguel Servet

Zaragoza, , Spain

Site Status

Changhua Christian Hospital

Changhua, , Taiwan

Site Status

Taichung Veterans General Hospital

Taichung, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Chang Gung Memorial Hospital Linkou Branch

Taoyuan, , Taiwan

Site Status

Gazi University Medical Faculty

Ankara, , Turkey (Türkiye)

Site Status

Istanbul University Cerrahpasa Medical Faculty

Istanbul, , Turkey (Türkiye)

Site Status

Acibadem Kozyatagi Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Ege University Medical Faculty

Izmir, , Turkey (Türkiye)

Site Status

Mersin University Medical Faculty Hospital

Mersin, , Turkey (Türkiye)

Site Status

Hull University Teaching Hospitals NHS Trust

Hull, , United Kingdom

Site Status

London North West University Healthcare NHS Trust

London, , United Kingdom

Site Status

Guys and St Thomas NHS Foundation Trust

London, , United Kingdom

Site Status

St Georges University Hospital NHS Foundation Trust

London, , United Kingdom

Site Status

Newcastle upon Tyne Hospitals NHS Foundation Trust

Newcastle upon Tyne, , United Kingdom

Site Status

Pennine Acute Hospitals NHS Trust

Salford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden United States Australia Belgium Canada Czechia Egypt France Germany Greece Hungary Israel Italy Japan Jordan Netherlands Poland Portugal Saudi Arabia South Korea Spain Taiwan Turkey (Türkiye) United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CNTO1959CRD3005

Identifier Type: OTHER

Identifier Source: secondary_id

2021-000491-10

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

2023-504740-33-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

CR109189

Identifier Type: -

Identifier Source: org_study_id